WO1995028934A2 - Utilisation d'inhibiteurs de mao-a dans la fabrication d'un medicament destine au traitement du syndrome de privation chez les fumeurs - Google Patents

Utilisation d'inhibiteurs de mao-a dans la fabrication d'un medicament destine au traitement du syndrome de privation chez les fumeurs Download PDF

Info

Publication number
WO1995028934A2
WO1995028934A2 PCT/EP1995/001492 EP9501492W WO9528934A2 WO 1995028934 A2 WO1995028934 A2 WO 1995028934A2 EP 9501492 W EP9501492 W EP 9501492W WO 9528934 A2 WO9528934 A2 WO 9528934A2
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
mao
manufacture
smokers
treatment
Prior art date
Application number
PCT/EP1995/001492
Other languages
English (en)
Other versions
WO1995028934A3 (fr
Inventor
Roman Amrein
Ivan Berlin
Alain Puech
Original Assignee
F. Hoffmann-La Roche Ag
Assistance Publique-Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Assistance Publique-Hopitaux De Paris filed Critical F. Hoffmann-La Roche Ag
Priority to AU24468/95A priority Critical patent/AU2446895A/en
Publication of WO1995028934A2 publication Critical patent/WO1995028934A2/fr
Publication of WO1995028934A3 publication Critical patent/WO1995028934A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Definitions

  • the present invention is concerned with a method for the control of the consumption of tobacco products and, respectively, of withdrawal symptoms which occur among smokers, especially when they make efforts to reduce smoking or to give it up completely.
  • the invention is accordingly concerned with the use of MAO-A inhibitors for the treatment and prevention of withdrawal symptoms caused by the consumption of tobacco products and the use of MAO-A inhibitors as active substances for the manufacture of medicaments for the said purpose.
  • MAO-A inhibitors which can be used in accord- ance with the invention are the benzamides described in US Patent 4 210 754, especially p-chloro-N-(2-morpholinoethyl)- benzamide (moclobemide), as well as compounds such as toloxatone and befloxatone.
  • the MAO-A inhibitors can be used in conventional commercial formulations, preferably in oral administration forms, e.g. as tablets, drag ⁇ es or capsules.
  • the active substances can be processed with pharmaceut ⁇ ically inert, inorganic or organic excipients for the manufacture of tablets, coated tablets, drag ⁇ es and hard gelatine capsules.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used e.g. as such excipients for tablets, drag ⁇ es and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • the pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or anti- oxidants. They can also contain still other therapeutically valuable substances.
  • the active substances are administered in doses which come into consideration or which are recommended for their known pharmaceutical use.
  • the convenient dose is about 100- 600 mg, preferably 300-450 mg, per day for an adult.
  • the treatment with the MAO-A inhibitor commences before breaking the habit (withdrawal of the tobacco product), e.g. 1 -2 weeks previously, and is continued for at least about 6 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de la monoamine oxydase-A dans la fabrication de médicaments destinés à lutter contre la consommation des produits du tabac et, en même temps, à limiter chez les fumeurs le syndrome de privation.
PCT/EP1995/001492 1994-04-22 1995-04-20 Utilisation d'inhibiteurs de mao-a dans la fabrication d'un medicament destine au traitement du syndrome de privation chez les fumeurs WO1995028934A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24468/95A AU2446895A (en) 1994-04-22 1995-04-20 Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1256/94-9 1994-04-22
CH125694 1994-04-22

Publications (2)

Publication Number Publication Date
WO1995028934A2 true WO1995028934A2 (fr) 1995-11-02
WO1995028934A3 WO1995028934A3 (fr) 1995-11-16

Family

ID=4206136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001492 WO1995028934A2 (fr) 1994-04-22 1995-04-20 Utilisation d'inhibiteurs de mao-a dans la fabrication d'un medicament destine au traitement du syndrome de privation chez les fumeurs

Country Status (2)

Country Link
AU (1) AU2446895A (fr)
WO (1) WO1995028934A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006139A2 (fr) * 1998-07-31 2000-02-10 Vela Pharmaceuticals Inc. Procedes et compositions pour le traitement et la prevention des toxicomanies a l'aide de moclobemide
FR2788982A1 (fr) * 1999-02-02 2000-08-04 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
WO2008143553A1 (fr) 2007-05-23 2008-11-27 Viktor Ivanovich Roschin Médicament servant au traitement de patients souffrant de maladies provoquées par l'activité excessive de la monoaminooxydase et méthode de traitement de patients souffrant de maladies provoquées par l'activité excessive de la monoaminooxydase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004387A2 (fr) * 1988-10-26 1990-05-03 Massachusetts Institute Of Technology Composition de traitement de symptomes relatifs au manque de tabac

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004387A2 (fr) * 1988-10-26 1990-05-03 Massachusetts Institute Of Technology Composition de traitement de symptomes relatifs au manque de tabac

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006139A2 (fr) * 1998-07-31 2000-02-10 Vela Pharmaceuticals Inc. Procedes et compositions pour le traitement et la prevention des toxicomanies a l'aide de moclobemide
WO2000006139A3 (fr) * 1998-07-31 2000-05-04 Janus Pharmaceuticals Inc Procedes et compositions pour le traitement et la prevention des toxicomanies a l'aide de moclobemide
FR2788982A1 (fr) * 1999-02-02 2000-08-04 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
WO2000045846A1 (fr) * 1999-02-02 2000-08-10 Sanofi-Synthelabo Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
WO2008143553A1 (fr) 2007-05-23 2008-11-27 Viktor Ivanovich Roschin Médicament servant au traitement de patients souffrant de maladies provoquées par l'activité excessive de la monoaminooxydase et méthode de traitement de patients souffrant de maladies provoquées par l'activité excessive de la monoaminooxydase

Also Published As

Publication number Publication date
AU2446895A (en) 1995-11-16
WO1995028934A3 (fr) 1995-11-16

Similar Documents

Publication Publication Date Title
US20020019421A1 (en) Compositions and therapy for substance addiction
JP6010572B2 (ja) 嗜癖の予防および治療のための組成物および方法
EP1019088B1 (fr) Composition de traitement de la dependance a la nicotine contenant mecamylamine et bupropion
US6376550B1 (en) Pharmaceutical compositions containing tramadol for migraine
US5869503A (en) Nicotine metabolites and human body weight
US20110268809A1 (en) Nicotine-Containing Pharmaceutical Compositions
US5030645A (en) Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof
US20100267735A1 (en) Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
JP6163289B2 (ja) 嗜癖の予防および治療のための組成物および方法
KR20020097182A (ko) 수면을 개선시키는 방법 및 조성물
JP7216697B2 (ja) 無煙タバコ中毒処置用のカンナビジオールおよびニコチンを含有する医薬製剤
WO1998020814A1 (fr) Metabolites de la nicotine, dependance a la nicotine et poids corporel d'un humain
EA004101B1 (ru) Применение селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
US10064850B2 (en) Compositions and methods for prophylaxis and treatment of addictions
US5747512A (en) Use of cotinine to alleviate tobacco withdrawal syndrome
PL196334B1 (pl) Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów
EP1033979B2 (fr) Combinaisons d'inhibiteurs des enzymes cyp2a6 et de nicotine et leur utilisation therapeutique
WO1995028934A2 (fr) Utilisation d'inhibiteurs de mao-a dans la fabrication d'un medicament destine au traitement du syndrome de privation chez les fumeurs
US5414005A (en) Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
JPH0699310B2 (ja) アセトアルデヒド解毒剤
JP2001504484A (ja) ネファゾドンの外傷後ストレス障害における使用
US20020168403A1 (en) Compositions and therapy for substance addiction
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
US20190022077A1 (en) Compositions and methods for prophylaxis and treatment of addictions
AU1045695A (en) Use of lobeline for the treatment of nicotine withdrawal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: CA

122 Ep: pct application non-entry in european phase